Updated analysis – OlympiA study: Chance of cure in early and locally advanced gBRCA-associated breast cancer
https://doi.org/10.33667/2078-5631-2023-10-51-57
Abstract
PARP inhibitors have been successfully used in the treatment of BRCA-associated metastatic breast cancer in recent years. Adjuvant therapy for gBRCAm carriers with HER 2-negative high-risk early-stage breast cancer has become a new indication for the use of olaparib.
This publication highlights the results of an updated analysis of the OlympiA trial that has changed clinical practice. Adjuvant treatment with olaparib for 1 year signifiantly increased survival rates. Four-year IDFS for the olaparib group was 82.7 % vs 75.4 % for placebo group.
Four-year OS was 89.8 % in the olaparib group and 86.4 % in the placebo group. The treatment has a favorable safety profie and does not reduce quality of life. Despite impressive results the OlympiA study raises many questions about the possibilities of integrating PARP inhibitors into modern standards for the treatment of early breast cancer. The main points of contention and possible ways to resolve them are discussed in this review.
About the Authors
E. V. Lubennikova
National Medical Research Centre of Oncology n.a. N. N. Blokhin
Russian Federation
Russian Federation
Lubennikova Elena V., PhD Med, senior researcher at Dept of Medicinal Methods of Treatment № 1
Moscow
E. V. Artamonova
National Medical Research Centre of Oncology n.a. N. N. Blokhin; Russian National Research Medical University n.a. N. I. Pirogov; Moscow Regional Research Clinical Institute n.a. M. F. Vladimirsky
Russian Federation
Russian Federation
Artamonova Elena V., DM Sci (habil.), head of Dept of Medicinal Methods of Treatment № 1 , professor at Dept of Oncology and Radiation Therapy, head of Dept of Oncology and Thoracic Surgery.
Moscow
References
1. Ray-Coquard I., Pérol D., Pujade-Lauraine E. PARP Inhibitors in Ovarian Cancer. Reply. The New England Journal of Medicine. 2020; 382 (16): 1574–1575. https://doi.org/10.1056/nejmc2000644
2. Pujade-Lauraine E., Ledermann J. A., Selle F., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 2017; 18 (9): 1274–1284. https://doi.org/10.1016/S 1470–2045(17)30469–2
3. González-Martín A., Pothuri B., Vergote I., et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2019; 381 (25): 2391–2402. https://doi.org/10.1056/NEJMoa1910962
4. Del Campo J. M., Matulonis U. A., Malander S., et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology. 2019; 37 (32): 2968–2973. https://doi.org/10.1200/jco.18.02238
5. Артамонова Е. В., Коваленко Е. И., Снеговой А. В., et al. Олапариб в поддерживающей терапии платиночувствительных рецидивов BRCA-ассоциированного рака яичников в реальной клинической практике: первые результаты наблюдательного исследования в российской популяции пациенток. Современная онкология. 2018; 20 (3): 19–25. https://doi.org/10.26442/1815–1434_2018.3.19–25
6. Artamonova E. V., Kovalenko E. I., Snegovoy A. V., et al. Olaparib in maintenance therapy of platinum-sensitive relapses of BRCA-associated ovarian cancer in real clinical practice: First results of an observational study in the Russian patient population. Modern oncology. 2018; 20 (3): 19–25. https://doi.org/10.26442/181 5–1434_2018.3.19–25
7. Golan T., Hammel P., Reni M., et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. New England Journal of Medicine. 2019; 381 (4): 317–327. https://doi.org/10.1056/NEJMoa1903387
8. de Bono J., Mateo J., Fizazi K., et al. Olaparib for metastatic castration-resistant prostate cancer. New England Journal of Medicine. 2020; 382 (22): 2091–2102. https://doi.org/10.1056/NEJMoa1903387
9. Матвеев В. Б., Халмурзаев О. А., Евсюкова О. И. et al. Международный опыт применения олапариба при метастатическом кастрационно-резистентном раке предстательной железы: обзор литературы. Онкоурология. 2020; 4: 197–206. https://doi.org/10.17650/1726–9776–2020–16–4–197–206
10. Matveev V. B., Khalmurzaev O. A., Evsyukova O. I. et al. International experience with olaparib in metastatic castration-resistant prostate cancer: a review of the literature. Oncourology. 2020; 4: 197–206. https://doi.org/10.17650/1726–9776–2020–16–4–197–206
11. Robson M., Im S. A., Senkus E., Xu B., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine. 2017; 377 (6): 523–533. https://doi.org/10.1056/nejmoa1706450
12. Litton J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753–763 (2018). Litton J. K., Rugo H. S., Ettl J., et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine. 2018; 379 (8): 753–763. https://doi.org/10.1056/nejmoa1802905
13. Tutt A. N., Garber J. E., Kaufman B., et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer. New England Journal of Medicine. 2021; 384 (25): 2394–2405. https://doi.org/10.1056/NEJMoa2105215
14. Tutt A. N.J.; Garber J.; Gelber R. D. et al. Prespecifid Event-Driven Analysis of Overall Survival in the OlympiA Phase III Trial of Adjuvant Olaparib in Germline BRCA1/2 Mutation Associated Breast Cancer. In ESMO Virtual Plenary. Abstract VP1–2022; ESMO: Lugano, Switzerland, 2022.
15. Geyer Jr C. E., Garber J. E., Gelber R. D., et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of oncology. 2022; 33 (12): 1250–1268. https://doi.org/10.1016/j.annonc.2022.09.159
16. Atchley D. P., Albarracin C. T., Lopez A., et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008; 26 (26): 4282–8. https://doi.org//10.1200/JCO.2008.16.6231
17. Beitsch P. D., Whitworth P. W., Hughes K., et al. Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle? Journal of Clinical Oncology. 2019; 37 (6): 453–460. https://doi.org/10.1200/JCO.18.01631
18. Yadav S., Hu C., Hart S. N., et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. Journal of Clinical Oncology. 2020; 38 (13): 1409–1418. https://doi.org/10.1200/jco.19.02190
19. Kurian AW, Griffih KA, Hamilton AS, et al. Genetic Testing and Counseling Among Patients with Newly Diagnosed Breast Cancer. JAMA. 2017; 317 (5): 531–534. https://doi.org/10.1001/jama.2016.16918
20. Kurian A. W., Ward K. C., Howlader N., et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. Journal of Clinical Oncology. 2019; 37 (15): 1305–1315. https://doi.org/10.1200/jco.18.01854
21. Childers C. P., Childers K. K., Maggard-Gibbons M., et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. Journal of Clinical Oncology. 2017; 35 (34): 3800–3806. https://doi.org/10.1200/jco.2017.73.6314
22. McCarthy A.M., Bristol M., Domchek S. M., et al. Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer. Journal of Clinical Oncology. 2016; 34 (22): 2610–2618. https://doi.org/10.1200/jco.2015.66.0019
23. Knerr S., Bowles E. J., Leppig K. A., et al. Trends in BRCA test utilization in an integrated health system, 2005–2015. JNCI: Journal of the National Cancer Institute. 2019; 111 (8): 795–802. https://doi.org/10.1093/jnci/djz008
24. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017; 376 (22): 2147–2159. https://doi.org/10.1056/nejmoa1612645
25. van Mackelenbergh MT, Seither F, Möbus V, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy e a meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. Eur J Cancer. 2022; 166: 185–201. https://doi.org/10.1016/j.ejca.2022.02.003
26. Lluch A, Barrios CH, Torrecillas L, et al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003–11_CIBOMA/2004–01). J Clin Oncol. 2020; 38 (3): 203–213. https://doi.org/10.1200/jco.19.00904
27. Tung N. M., Zakalik D., Somerfild M. R. Hereditary Breast Cancer Guideline Expert Panel. Adjuvant PARP Inhibitors in Patients with High-Risk Early-Stage HER 2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. J. Clin. Oncol. 2021, 39, 2959–2961. https://doi.org/10.1200/jco.21.01532
28. Johnston S. R., Toi M., O’Shaughnessy J., et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER 2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet Oncology. 2023; 24 (1): 77–90. https://doi.org/10.1016/s1470–2045(22)00694–5
29. Johnston S. R., Harbeck N., Hegg R., et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER 2–, node-positive, high-risk, early breast cancer (monarchE). Journal of Clinical Oncology. 2020; 38 (34); 3987–3998. https://doi.org/10.1200/jco.20.02514
30. Safonov A, Bandlamudi C, Tallon de Lara P, et al. Comprehensive genomic profiing of patients with breast cancer identifis germlinesomatic interactions mediating therapy resistance. SABCS. 2021; 82 (suppl 4): abstr GS 4–08.
31. Kim JY, Oh JM, Park YH, et al. Which clinicopathologic parameters suggest primary resistance to palbociclib in combination with letrozole as the fist-line treatment for hormone receptor-positive, HER 2-negative advanced breast cancer? Front Oncol. 2021; 11: 759150. https://doi.org/10.3389/fonc.2021.759150
32. Bruno L, Ostinelli A, Waisberg F, et al. Cyclin-dependent kinase 4/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair-related genes. JCO Precis Oncol. 2022; 6: e2100140. https://doi.org/10.1200/po.21.00140
33. Tung N., Garber J. E. PARP inhibition in breast cancer: Progress made and future hopes. NPJ Breast Cancer. 2022; 8 (1); 47. https://doi.org/10.1038/s41523–022–00411–3
34. Iwamoto T., Booser D., Valero V., et al Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1 % to 10 % ER-positive by immunohistochemistry. J Clin Oncol. 2012; 30 (7): 729–734. https://doi.org/10.1200/jco.2011.38.9619
35. Deyarmin B., Kane J. L., Valente A. L., et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Annals of Surgical Oncology. 2013; 20: 87–93. https://doi.org/10.1245/s10434–012–2588–8
36. Gloyeske N. C., Dabbs D. J. Bhargava R. Low ER+ breast cancer: Is this a distinct group? Am. J. Clin. Pathol. 141, 697–701 (2014). https://doi.org/10.1309/ajcp-34cysatwfdpq
37. Moore K., Colombo N., Scambia G., et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2018; 379 (26): 2495–2505. https://doi.org/10.1056/nejmoa1810858
38. Gonzalez-Martin A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019). González-Martín A., Pothuri B., Vergote I., et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2019; 381 (25): 2391–2402. https://doi.org/10.1056/nejmoa1910962
39. Madariaga A, Bowering V, Ahrari S, et al. Manage wisely: poly (ADPribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer. 2020; 30 (7): 903–915. http://dx.doi.org/10.1136/ijgc-2020–001288
40. Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specifi survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29: 1956–62. https://doi.org/10.1200/jco.2010.31.8469
Review
For citations:
Lubennikova E.V., Artamonova E.V. Updated analysis – OlympiA study: Chance of cure in early and locally advanced gBRCA-associated breast cancer. Medical alphabet. 2023;(10):51-57. (In Russ.) https://doi.org/10.33667/2078-5631-2023-10-51-57
Views:
671
Email this article 